Test | Cornell BioVentures

Mid-sized European drugmakers are snapping up US biotechs. Will the surge continue?

May 13, 2026

European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the...

Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge

May 12, 2026

After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.

Angelini inks $4.1B Catalyst buy to enter US rare disease market

May 7, 2026

Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.

GSK goes beyond weight-loss with $1B buyout of Chinese siRNA specialist

May 7, 2026

With Siran Biotechnology under its fold, GSK will have access to a long-acting siRNA therapy that could induce weight loss while preserving lean mass, in...

Amgen, Sanofi commit nearly $600M to North American expansions

May 6, 2026

Sanofi’s investment will support a Canadian site’s efforts to apply AI to drug production, while Amgen has unveiled the second expansion of its Puerto Rico...

CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026

May 6, 2026

Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.

Bayer ends multi-year M&A drought with up to $2.45B Perfuse buy

May 6, 2026

For $300 million upfront, Bayer is purchasing Perfuse Therapeutics to advance an eye implant for glaucoma and diabetic retinopathy, marking the company’s first pharma acquisition...

Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening

May 6, 2026

First quarter earnings continue to arrive, with analysts demanding more from cautious Pfizer and Eli Lilly expecting more revenue; the FDA taps Katherine Szarama as...

Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead

May 5, 2026

Madrigal Pharmaceuticals has licensed from Arrowhead Pharmaceuticals an RNA interference candidate that targets a genetic mutation present in around 30% of patients with MASH.

Merck drops early-stage TROP ADC, keeps deal doors open as Keytruda clock ticks

April 30, 2026

On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic spaces—as the quest continues for a...